Welcome
We manage the Government's investment in health research. Our vision is to improve the health and quality of life of all New Zealanders.
Funding Opportunities
The HRC allocates funding through an annual funding round for researcher initiated projects, Requests for Proposals, and a range of career development awards.
About Us
We invest in a broad range of research on issues important to New Zealand, and support the development of health research careers. Our mission is 'benefiting New Zealand through health research'.
News and Publications
We produce a wide range of publications and documents, which provide information about funding opportunities, research outcomes and HRC-related news.
Ethics and Regulatory
We help ensure all research involving human participants is based on good science, meets ethical standards and complies with best practice.
Contact Us
If you have any questions about the HRC or would like to know more about how our funding process works, please drop us a line.
Gene Technology Advisory Committee
Dr Janak de Zoysa
2014 Funding Round – Project
Dr
Janak
de Zoysa
Waitemata District Health Board
CKD-FIX: Trial of xanthine oxidase inhibition to slow kidney disease progression
$990,685
48 months
Lay summary
Chronic kidney disease is a major public health issue that is estimated to affect 10% of New Zealanders. Chronic kidney disease increases the risk of kidney failure, premature heart disease and death. Kidney failure causes a significant social and financial burden to patients and their families and generates a significant cost to the NZ public health system.
Current therapies to slow or prevent chronic kidney disease are only partly effective with many patients developing kidney failure despite optimal therapy.
Experimental animal studies and small clinical studies suggest that lowering uric acid may be helpful to slow or prevent the progression of kidney disease.
This is a multi-centre, multi-national double-blind, randomised trial which will enrol 100 New Zealand patients who will receive allopurinol or a placebo. It will determine whether therapy to lower uric acid can slow the progression of chronic kidney disease, reduce cardiovascular events and reduce mortality.
Print